/ /

  • linkedin
  • Increase Font
  • Sharebar

    Dr. Mali's top 5 stories in ophthalmology in 2017 (so far)

     

    5) Ophthalmic industry mergers/acquisitions continue    

    As predicted by my previous article in December 2016 (please see Dr. Mali's top 5 predictions in ophthalmology for 2017)2, ophthalmic industry mergers and acquisitions are increasing at a rapid rate; 2017 has already seen such industry maneuvers such as Johnson & Johnson's acquisition of TearScience, Inotek Pharmaceuticals entering into a definitive merger agreement with Rocket Pharmaceuticals, and Luxottica Group (maker of Ray-Ban sunglasses) merging with French optical-lens maker Essilor International, just to name a few of these industry collaborations.

    I would not be surprised to see a few more of these types of deals before the end of 2017. 

    So far, 2017 has been a very exciting year for both ophthalmology and healthcare as a whole. We still have a few months left for more excitement, so stay tuned!

     

    References

    1.  https://abop.org/maintain-certification/pilot-programs/

    2.  Mali, Joshua. Dr. Mali's top 5 predictions in ophthalmology for 2017. Ophthalmology Times. December 24, 2016.

     

     

    Joshua Mali, MD, is a board certified ophthalmologist and vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida. He can be reached at 941-923-2020. He is currently a consultant for Regeneron Pharmaceuticals, where he also conducts research and receives clinical study funding.

    Joshua Mali, MD
    Joshua Mali, MD, is a vitreoretinal surgeon at The Eye Associates, a private multispecialty ophthalmology practice in Sarasota, Florida.

    New Call-to-action

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll

    View Results